Intelligence Report · ~12 min read

Lupin Ltd. Intelligence Report

Generated from 2 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Jun 21, 2026

Confidence

Moderate Confidence · 60%

Evidence

12 items

Sources

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Lupin Ltd. maintains an active intelligence profile across Cardiovascular, Antihypertensive, Neurology, Antiepileptic. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 60% across 2 tracked sources. Highest-priority development: FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin Ltd.; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

regulatory
FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — LOSARTAN POTASSIUM (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — LOSARTAN POTASSIUM (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — LOSARTAN POTASSIUM (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — DIVALPROEX SODIUM (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — DIVALPROEX SODIUM (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — DIVALPROEX SODIUM (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — DIVALPROEX SODIUM (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 42 with buyer quality 4 (Low Priority). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — LOSARTAN POTASSIUM (SUPPL)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — LOSARTAN POTASSIUM (SUPPL)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (ORIG)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — LOSARTAN POTASSIUM (SUPPL)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)
Low Confidence · 54%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — DIVALPROEX SODIUM (SUPPL)
Low Confidence · 54%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — DIVALPROEX SODIUM (SUPPL)
Low Confidence · 54%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — DIVALPROEX SODIUM (SUPPL)
Low Confidence · 54%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — DIVALPROEX SODIUM (SUPPL)
Low Confidence · 54%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

Lupin's ANDA078232 for Losartan Potassium Receives AP Status from FDA
Cardiovascular · Antihypertensive
Lupin's Divalproex Sodium ANDA209286 Receives Abbreviated Approval
Neurology · Antiepileptic

Executive Summary

Key Developments

FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)

FDA AP — LOSARTAN POTASSIUM (SUPPL)

FDA AP — LOSARTAN POTASSIUM (SUPPL)

FDA AP — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (ORIG)

FDA AP — LOSARTAN POTASSIUM (SUPPL)

FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)

FDA AP — DIVALPROEX SODIUM (SUPPL)

FDA AP — DIVALPROEX SODIUM (SUPPL)

FDA AP — DIVALPROEX SODIUM (SUPPL)

FDA AP — DIVALPROEX SODIUM (SUPPL)

Strategic Implications

Supporting Evidence

FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)

FDA AP — LOSARTAN POTASSIUM (SUPPL)

FDA AP — LOSARTAN POTASSIUM (SUPPL)

FDA AP — LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE (ORIG)

FDA AP — LOSARTAN POTASSIUM (SUPPL)

FDA AP — SODIUM SULFATE, MAGNESIUM SULFATE AND POTASSIUM CHLORIDE (ORIG)

FDA AP — DIVALPROEX SODIUM (SUPPL)

FDA AP — DIVALPROEX SODIUM (SUPPL)

FDA AP — DIVALPROEX SODIUM (SUPPL)

FDA AP — DIVALPROEX SODIUM (SUPPL)

Related Intelligence

Signals